2026 Reports — AbbVie

AbbVie grew revenue 12.4% to $15.0bn and lifted adjusted EPS 7.7% to $2.65, but reported EPS fell 46% to $0.39 on a $2.4bn contingent-consideration charge triggered by its own raised Skyrizi forecast and a $650m RemeGen licence payment.

Revenue grew 9.5% on constant currency as Skyrizi and Rinvoq (both +24%) continue to outrun Humira's decline (-36%); GAAP EPS growth of 290% is a base-effect artifact of intangible amortization and contingent-consideration accounting, not operating performance.